Radionuclide imaging of bone marrow disorders

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 1, 2011, Pages 166-178

  Agool, Ali ^a,b   Glaudemans, Andor W J M ^b   Boersma, Hendrikus H ^b   Dierckx, Rudi A J O ^b,c   Vellenga, Edo ^b   Slart, Riemer H J A ^b  

^a Department of Nuclear Medicine   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Bone marrow disorders; Bone marrow imaging

Indexed keywords

HEMOPOIETIC GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; RADIOISOTOPE; TRACER;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; BLOOD TRANSFUSION; BONE MARROW DISEASE; BONE MARROW METASTASIS; BONE MARROW TRANSPLANTATION; CANCER GROWTH; CANCER RADIOTHERAPY; EXTRAMEDULLARY HEMATOPOIESIS; HEMOLYTIC ANEMIA; HUMAN; IMAGE ANALYSIS; MEDICAL LITERATURE; METABOLISM; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; MYELOPROLIFERATIVE DISORDER; POSITRON EMISSION TOMOGRAPHY; RADIODIAGNOSIS; RETICULOENDOTHELIAL SYSTEM; REVIEW; SCINTISCANNING;

ANIMALS; BONE MARROW DISEASES; CELL PROLIFERATION; HUMANS; RADIONUCLIDE IMAGING;

EID: 79551527605     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1531-0     Document Type: Review

References (77)

1. Rubin R, Strayer DS. Rubin's pathology: clinicopathologic foundations of medicine. Philadelphia: Lippincott Williams & Wilkins; 2007.
2. A Rizo E Vellenga G de Haan JJ Schuringa 2009 Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche? Hum Mol Genet 15 Spec no 2 R210 R219
3. HE Johnsen MK Kjeldsen T Urup K Fogd L Pilgaard M Boegsted, et al. 2009 Cancer stem cells and the cellular hierarchy in haematological malignancies Eur J Cancer 45 Suppl 1 194 201 10.1016/S0959-8049(09)70033-4 19775618
4. Vardimann JW. Myelodysplastic/myeloproliferative diseases. In: Finn WG, Peterson LC, editors. Hematopathology in oncology. New York: Springer US; 2004. p. 13-43.
5. H Schepers D van Gosliga AT Wierenga BJ Eggen JJ Schuringa E Vellenga 2007 STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells Blood 110 2880 2888 1:CAS:528:DC%2BD2sXht1Smu77M 10.1182/blood-2006-08-039073 17630355 (Pubitemid 350006941)
6. CA Koch CY Li RA Mesa A Tefferi 2003 Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment Mayo Clin Proc 78 1223 1233 10.4065/78.10.1223 14531481
7. S Charache DL Page 1967 Infarction of bone marrow in the sickle cell disorders Ann Intern Med 67 1195 1200 1:STN:280:DyaF1c%2Fls1SgsA%3D%3D 6061934
8. LG Lutzker A Alavi 1976 Bone and marrow imaging in sickle cell disease: diagnosis of infarction Semin Nucl Med 6 83 93 1:STN:280:DyaE287gsVKrtg%3D%3D 10.1016/S0001-2998(76)80038-4 1108210
9. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2009.
10. F Delhommeau S Dupont V Della Valle C James S Trannoy A Masse, et al. 2009 Mutation in TET2 in myeloid cancers N Engl J Med 360 2289 2301 10.1056/NEJMoa0810069 19474426
11. Jaffe ES, Harris NL, Stein H, Vardiman JW. Tumours of haematopoietic and lymphoid tissue, pathology and genetics. World Health Organization classification of tumours. Lyon: IARC Press, 2001.
12. A Tefferi JL Spivak 2005 Polycythemia vera: scientific advances and current practice Semin Hematol 42 206 220 1:CAS:528:DC%2BD2MXhtF2ju7vJ 10.1053/j.seminhematol.2005.08.003 16210034 (Pubitemid 41400662)
13. J Tennvall B Brans 2007 EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases Eur J Nucl Med Mol Imaging 34 1324 1327 10.1007/s00259-007-0407-4 17396258 (Pubitemid 47290669)
14. CS Tam H Kantarjian J Cortes A Lynn S Pierce L Zhou, et al. 2009 Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis J Clin Oncol 27 5587 5593 10.1200/JCO.2009.22.8833 19786661
15. P Greenberg J Anderson T de Witte E Estey P Fenaux P Gupta, et al. 2000 Problematic WHO reclassification of myelodysplastic syndromes Members of the International MDS Study Group J Clin Oncol 18 3447 3452 1:STN:280: DC%2BD3M%2FgvFWksg%3D%3D 11013289
16. PJ Williamson AR Kruger PJ Reynolds TJ Hamblin DG Oscier 1994 Establishing the incidence of myelodysplastic syndrome Br J Haematol 87 743 745 1:STN:280:DyaK2M%2FnvVWnsQ%3D%3D 10.1111/j.1365-2141.1994.tb06733.x 7986716
17. NS Young 2002 Acquired aplastic anemia Ann Intern Med 136 534 546 11926789
18. NS Young P Scheinberg RT Calado 2008 Aplastic anemia Curr Opin Hematol 15 162 168 10.1097/MOH.0b013e3282fa7470 18391779 (Pubitemid 351507566)
19. LA Pitcher IM Hann JP Evans P Veys JM Chessells DK Webb 1999 Improved prognosis for acquired aplastic anaemia Arch Dis Child 80 158 162 1:STN:280:DyaK1M3lslGrsA%3D%3D 10.1136/adc.80.2.158 10325732
20. AG Desai ML Thakur 1985 Radiopharmaceuticals for spleen and bone marrow studies Semin Nucl Med 15 229 238 1:STN:280:DyaL2MzgtVGrug%3D%3D 10.1016/S0001-2998(85)80002-7 2994232
21. SN Reske 1991 Recent advances in bone marrow scanning Eur J Nucl Med 18 203 221 1:STN:280:DyaK3M3kvFyqtg%3D%3D 10.1007/BF02262732 2040342
22. PF Milner M Brown 1982 Bone marrow infarction in sickle cell anemia: correlation with hematologic profiles Blood 60 1411 1419 1:STN:280: DyaL3s%2FkvFGktQ%3D%3D 7139126
23. JS Blebea M Houseni DA Torigian C Fan A Mavi Y Zhuge, et al. 2007 Structural and functional imaging of normal bone marrow and evaluation of its age-related changes Semin Nucl Med 37 185 194 10.1053/j.semnuclmed.2007.01.002 17418151 (Pubitemid 46517466)
24. A Ferrant J Rodhain N Leners M Cogneau RL Verwilghen JL Michaux, et al. 1986 Quantitative assessment of erythropoiesis in bone marrow expansion areas using 52Fe Br J Haematol 62 247 255 1:STN:280:DyaL287jtFChsQ%3D%3D 10.1111/j.1365-2141.1986.tb02928.x 3947548
25. FL Datz A Taylor Jr 1985 The clinical use of radionuclide bone marrow imaging Semin Nucl Med 15 239 259 1:STN:280:DyaL2MzgtVGruw%3D%3D 10.1016/S0001-2998(85)80003-9 2994233
26. H Itoh M Kanamori N Takahashi 1990 Dissociation between In-111 chloride and Tc-99m colloid bone marrow scintigraphy in refractory anemia with excess blasts Clin Nucl Med 15 124 125 1:STN:280:DyaK3c7otlWmsQ%3D%3D 10.1097/00003072-199002000-00017 2311325
27. BA Sayle RE Helmer III BA Birdsong S Balachandran FH Gardner 1982 Bone-marrow imaging with indium-111 chloride in aplastic anemia and myelofibrosis: concise communication J Nucl Med 23 121 125 1:STN:280: DyaL387itFymtQ%3D%3D 7057252
28. JD Rain Y Najean 1993 Bone marrow scintigraphy in myelofibrosis Nouv Rev Fr Hematol 35 101 102 1:STN:280:DyaK3s3ovVGgtg%3D%3D 8511031
29. BJ McNeil JM Rappeport DG Nathan 1976 Indium chloride scintigraphy: an index of severity in patients with aplastic anaemia Br J Haematol 34 599 604 1:STN:280:DyaE2s%2FksFeltA%3D%3D 10.1111/j.1365-2141.1976.tb03606.x 791343
30. T Hotta T Murate C Inoue T Kagami K Tsushita JY Wang, et al. 1990 Patchy haemopoiesis in long-term remission of idiopathic aplastic anaemia Eur J Haematol 45 73 77 1:STN:280:DyaK3M%2Fgs1Gjuw%3D%3D 10.1111/j.1600-0609.1990. tb00420.x 2209821
31. D Huic V Ivancevic WS Richter DL Munz 1997 Immunoscintigraphy of the bone marrow: normal uptake values of technetium-99m-labeled monoclonal antigranulocyte antibodies J Nucl Med 38 1755 1758 1:STN:280: DyaK1c%2FktVGjsQ%3D%3D 9374347
32. B Wahren G Gahrton S Hammarstrom 1980 Nonspecific cross-reacting antigen in normal and leukemic myeloid cells and serum of leukemic patients Cancer Res 40 2039 2044 1:STN:280:DyaL3c7nslSjsA%3D%3D 6929221
33. W Becker U Borst W Fischbach B Pasurka R Schafer W Borner 1989 Kinetic data of in-vivo labeled granulocytes in humans with a murine Tc-99m-labelled monoclonal antibody Eur J Nucl Med 15 361 366 1:STN:280:DyaL1Mznsl2mtA%3D%3D 10.1007/BF00449225 2776795
34. SN Reske JH Karstens W Gloeckner A Steinstrasser A Schwarz J Ammon, et al. 1989 Radioimmunoimaging for diagnosis of bone marrow involvement in breast cancer and malignant lymphoma Lancet 1 299 301 1:STN:280:DyaL1M7is1KlsA%3D%3D 10.1016/S0140-6736(89)91309-3 2563458
35. DL Munz E Voth D Emrich 1987 Different approaches to determine the uptake ratio of bone-marrow-seeking radiopharmaceuticals for classifying the scintigraphic bone marrow status Nuc Compact 18 192 194
36. Bonner H. Pathology. Philadelphia: Lippincott; 2009.
37. K Inoue R Goto K Okada S Kinomura H Fukuda 2009 A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity Ann Nucl Med 23 643 649 10.1007/s12149-009-0286-9 19629627
38. Y Sugawara SJ Fisher KR Zasadny PV Kison LH Baker RL Wahl 1998 Preclinical and clinical studies of bone marrow uptake of fluorine-1- fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy J Clin Oncol 16 173 180 1:CAS:528:DyaK1cXmtlOksQ%3D%3D 9440740
39. MV Knopp H Bischoff A Rimac F Oberdorfer G van Kaick 1996 Bone marrow uptake of fluorine-18-fluorodeoxyglucose following treatment with hematopoietic growth factors: initial evaluation Nucl Med Biol 23 845 849 1:CAS:528: DyaK28XmsFWmur0%3D 10.1016/0969-8051(96)00085-6 8940729 (Pubitemid 26342490)
40. S Basu R Asopa H Peshwe KM Mohandas 2008 Diffuse intense FDG uptake in the bone marrow in gastrointestinal stromal tumor with coexistent polycythemia rubra vera Clin Nucl Med 33 782 783 10.1097/RLU.0b013e318187ef9b 18936614
41. HM Quarles van Ufford JA de Jong HJ Baarslag MJ de Haas K Oud JM de Klerk JM 2008 FDG PET in a patient with polycythemia vera Clin Nucl Med 33 780 781 10.1097/RLU.0b013e318187ef59 18936613
42. SC Burrell AJ Fischman 2005 Myelofibrosis on F-18 FDG PET Imaging Clin Nucl Med 30 674 10.1097/01.rlu.0000178029.47624.66 16166839 (Pubitemid 41361757)
43. K Inoue K Okada H Harigae Y Taki R Goto S Kinomura, et al. 2006 Diffuse bone marrow uptake on F-18 FDG PET in patients with myelodysplastic syndromes Clin Nucl Med 31 721 723 10.1097/01.rlu.0000242685.55001.67 17053396 (Pubitemid 44624565)
44. SK Cheran JE Herndon EF Patz Jr 2004 Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer Lung Cancer 44 317 325 10.1016/j.lungcan.2003.11.008 15140545 (Pubitemid 38609440)
45. R Kumar A Alavi 2004 Fluorodeoxyglucose-PET in the management of breast cancer Radiol Clin N Am 42 1113 1122 10.1016/j.rcl.2004.08.005 15488561 (Pubitemid 39361463)
46. R Kumar I Maillard SJ Schuster A Alavi 2004 Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas Radiol Clin N Am 42 1083 1100 10.1016/j.rcl.2004.08.008 15488559 (Pubitemid 39361461)
47. A Mavi P Lakhani H Zhuang NC Gupta A Alavi 2005 Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer Radiol Clin N Am 43 1 21 10.1016/j.rcl.2004.09.001 15693644 (Pubitemid 40326556)
48. F Moog M Bangerter J Kotzerke A Guhlmann N Frickhofen SN Reske 1998 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow J Clin Oncol 16 603 609 1:STN:280:DyaK1c7ivFamsg%3D%3D 9469348
49. G Paone E Itti C Haioun P Gaulard J Dupuis C Lin, et al. 2009 Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate Eur J Nucl Med Mol Imaging 36 745 750 10.1007/s00259-008-1021-9 19096842
50. PY Salaun T Gastinne C Bodet-Milin L Campion P Cambefort A Moreau, et al. 2009 Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging 36 1813 1821 10.1007/s00259-009-1183-0 19499219
51. S Becker G Becker-Pergola D Wallwiener EF Solomayer T Fehm 2006 Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy Breast Cancer Res Treat 97 91 96 1:CAS:528:DC%2BD28Xks1Okur0%3D 10.1007/s10549-005-9095-6 16319975
52. T Endo N Sato K Koizumi M Nishio K Fujimoto T Sakai, et al. 2004 Localized relapse in bone marrow of extremities after allogeneic stem cell transplantation for acute lymphoblastic leukemia Am J Hematol 76 279 282 1:STN:280:DC%2BD2czitFejtw%3D%3D 10.1002/ajh.20106 15224367 (Pubitemid 38828851)
53. M Nakajo S Jinnouchi H Inoue M Otsuka T Matsumoto T Kukita, et al. 2007 FDG PET findings of chronic myeloid leukemia in the chronic phase before and after treatment Clin Nucl Med 32 775 778 10.1097/RLU.0b013e318148b467 17885356 (Pubitemid 47476342)
54. H Jadvar PS Conti 2002 Diagnostic utility of FDG PET in multiple myeloma Skeletal Radiol 31 690 694 10.1007/s00256-002-0580-2 12483429 (Pubitemid 36104567)
55. A Agool RH Slart RA Dierckx PM Kluin L Visser PL Jager, et al. 2010 Somatostatin receptor scintigraphy might be useful for detecting skeleton abnormalities in patients with multiple myeloma and plasmacytoma Eur J Nucl Med Mol Imaging 37 124 130 1:CAS:528:DC%2BD1MXhsFCktLrI 10.1007/s00259-009-1199-5 19597816
56. L Pace L Catalano A Pinto A De Renzo F Di Gennaro C Califano, et al. 1998 Different patterns of technetium-99m sestamibi uptake in multiple myeloma Eur J Nucl Med 25 714 720 1:CAS:528:DyaK1cXktlyju7k%3D 10.1007/s002590050274 9662593 (Pubitemid 28377034)
57. R Fonti B Salvatore M Quarantelli C Sirignano S Segreto F Petruzziello, et al. 2008 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma J Nucl Med 49 195 200 10.2967/jnumed.107.045641 18199607 (Pubitemid 351225656)
58. AF Shields JR Grierson BM Dohmen HJ Machulla JC Stayanoff JM Lawhorn-Crews, et al. 1998 Imaging proliferation in vivo with [F-18]FLT and positron emission tomography Nat Med 4 1334 1336 1:CAS:528:DyaK1cXntlaqsrk%3D 10.1038/3337 9809561 (Pubitemid 28512118)
59. AK Buck M Bommer ME Juweid G Glatting S Stilgenbauer FM Mottaghy, et al. 2008 First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine J Nucl Med 49 1756 1762 10.2967/jnumed.108.055335 18927328
60. A Agool BW Schot PL Jager E Vellenga 2006 18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment J Nucl Med 47 1592 1598 17015893
61. Woolthuis C, Agool A, Olthof S, Slart RH, Huls G, Smid WM, et al. Auto-SCT induces a phenotypic shift from CMP to GMP progenitors, reduces clonogenic potential and enhances in vitro and in vivo cycling activity defined by (18)F-FLT PET scanning. Bone Marrow Transplant 2010. DOI: 10.1038/bmt.2010.75
62. R Nunez HA Macapinlac HW Yeung T Akhurst S Cai I Osman, et al. 2002 Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer J Nucl Med 43 46 55 11801702
63. A Dankerl P Liebisch G Glatting C Friesen NM Blumstein D Kocot, et al. 2007 Multiple myeloma: molecular imaging with 11C-methionine PET/CT - initial experience Radiology 242 498 508 10.1148/radiol.2422051980 17179397 (Pubitemid 46146203)
64. M Cimitan R Bortolus S Morassut V Canzonieri A Garbeglio T Baresic, et al. 2006 [18F]Fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients Eur J Nucl Med Mol Imaging 33 1387 1398 10.1007/s00259-006-0150-2 16865395 (Pubitemid 44885404)
65. SA Kwee GP Thibault RS Stack MN Coel B Furusato IA Sesterhenn 2008 Use of step-section histopathology to evaluate 18F-fluorocholine PET sextant localization of prostate cancer Mol Imaging 7 12 20 18384719
66. QH Zheng TA Gardner S Raikwar C Kao KL Stone TD Martinez, et al. 2004 [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models Bioorg Med Chem 12 2887 2893 1:CAS:528:DC%2BD2cXktVKqtrk%3D 10.1016/j.bmc.2004. 03.051 15142549 (Pubitemid 38622124)
67. IJ de Jong J Pruim PH Elsinga W Vaalburg HJ Mensink 2002 Visualization of prostate cancer with 11C-choline positron emission tomography Eur Urol 42 18 23 10.1016/S0302-2838(02)00129-X 12121724 (Pubitemid 35345101)
68. P Shreve PC Chiao HD Humes M Schwaiger MD Gross 1995 Carbon-11-acetate PET imaging in renal disease J Nucl Med 36 1595 1601 1:STN:280: DyaK2MzoslWgsA%3D%3D 7658216
69. S Albrecht F Buchegger D Soloviev H Zaidi H Vees HG Khan, et al. 2007 (11)C-Acetate PET in the early evaluation of prostate cancer recurrence Eur J Nucl Med Mol Imaging 34 185 196 10.1007/s00259-006-0163-x 16832632 (Pubitemid 46147501)
70. DE Ponde CS Dence N Oyama J Kim YC Tai R Laforest, et al. 2007 18F-Fluoroacetate: a potential acetate analog for prostate tumor imaging - in vivo evaluation of 18F-fluoroacetate versus 11C-acetate J Nucl Med 48 420 428 1:CAS:528:DC%2BD2sXhtVertLzL 17332620
71. M Souvatzoglou AL Grosu B Roper BJ Krause R Beck G Reischl, et al. 2007 Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study Eur J Nucl Med Mol Imaging 34 1566 1575 1:STN:280: DC%2BD2srmtlWqsw%3D%3D 10.1007/s00259-007-0424-3 17447061 (Pubitemid 47476913)
72. A Padhani 2006 PET imaging of tumour hypoxia Cancer Imaging 6 S117 S121 10.1102/1470-7330.2007.0001 17114063
73. P Baumann S Mandl-Weber A Volkl C Adam I Bumeder F Oduncu, et al. 2009 Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells Mol Cancer Ther 8 366 375 1:CAS:528:DC%2BD1MXhvFamsLY%3D 10.1158/1535-7163.MCT-08-0664 19174558
74. B Neumaier FM Mottaghy AK Buck G Glatting NM Blumstein B Mahren, et al. 2008 (18)F-Immuno-PET: Determination of anti-CD66 biodistribution in a patient with high-risk leukemia Cancer Biother Radiopharm 23 819 824 1:CAS:528:DC%2BD1MXpsVaitg%3D%3D 10.1089/cbr.2008.0512 19111052
75. M Ringhoffer N Blumstein B Neumaier G Glatting S von Harsdorf I Buchmann, et al. 2005 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study Br J Haematol 130 604 613 1:CAS:528:DC%2BD2MXhtVentbzF 10.1111/j.1365-2141.2005.05663.x 16098076 (Pubitemid 43899765)
76. WB Nagengast EG de Vries GA Hospers NH Mulder JR de Jong H Hollema, et al. 2007 In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft J Nucl Med 48 1313 1319 1:CAS:528:DC%2BD2sXhtVSktb%2FE 10.2967/jnumed.107.041301 17631557 (Pubitemid 47242797)
77. ES de Bont S Rosati S Jacobs WA Kamps E Vellenga 2001 Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor Br J Haematol 113 296 304 10.1046/j.1365-2141.2001.02722.x 11380392 (Pubitemid 32523131)